Scancell Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Scancell HoldingsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 25% bzw. 22.4% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-22.4%

Wachstumsrate der Gewinne

-23.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	-25.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:SCP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
4/30/2027	N/A	N/A	-15	N/A	1
4/30/2026	N/A	-10	-14	-6	3
4/30/2025	2	-13	-11	-8	3
4/30/2024	N/A	-6	-16	-16	N/A
1/31/2024	N/A	-8	-13	-13	N/A
10/31/2023	N/A	-10	-11	-11	N/A
7/31/2023	3	-11	-9	-9	N/A
4/30/2023	5	-12	-8	-8	N/A
1/31/2023	5	-12	-9	-9	N/A
10/31/2022	5	-13	-11	-10	N/A
7/31/2022	3	-9	-11	-10	N/A
4/30/2022	N/A	-5	-11	-10	N/A
1/31/2022	N/A	-6	-11	-10	N/A
10/31/2021	N/A	-8	-11	-9	N/A
7/31/2021	N/A	-12	-10	-8	N/A
4/30/2021	N/A	-15	-9	-8	N/A
1/31/2021	N/A	-11	-7	-7	N/A
10/31/2020	N/A	-7	-6	-5	N/A
7/31/2020	N/A	-6	-5	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-5	-6	-6	N/A
7/31/2019	N/A	-5	-6	-6	N/A
4/30/2019	N/A	-6	-7	-7	N/A
1/31/2019	N/A	-6	-6	-6	N/A
10/31/2018	N/A	-5	-6	-6	N/A
7/31/2018	N/A	-5	-5	-5	N/A
4/30/2018	N/A	-4	-4	-4	N/A
1/31/2018	N/A	-4	N/A	-4	N/A
10/31/2017	N/A	-4	N/A	-4	N/A
7/31/2017	N/A	-4	N/A	-4	N/A
4/30/2017	N/A	-4	N/A	-4	N/A
1/31/2017	N/A	-3	N/A	-3	N/A
10/31/2016	N/A	-3	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-3	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-2	N/A	-2	N/A
10/31/2015	N/A	-2	N/A	-3	N/A
7/31/2015	N/A	-2	N/A	-3	N/A
4/30/2015	N/A	-2	N/A	-3	N/A
1/31/2015	N/A	-2	N/A	-2	N/A
10/31/2014	N/A	-2	N/A	-2	N/A
7/31/2014	N/A	-2	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SCP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SCP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SCP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SCPDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-25% pro Jahr).

Hohe Wachstumseinnahmen: SCPDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-25% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SCP in 3 Jahren voraussichtlich hoch sein wird

Scancell Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Scancell Holdings plc Announces Further Positive Data from the Ongoing SCOPE Trial of SCIB1 with Double CPIs for Advanced Melanoma

Scancell Holdings plc Announces CEO Changes

Scancell Holdings plc, Annual General Meeting, Oct 25, 2024

Scancell Holdings plc to Report Fiscal Year 2024 Results on Sep 24, 2024

New minor risk - Financial data availability

Scancell Holdings plc Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial

Scancell Holdings plc Announces That A Group of Medical Oncologists in the Field of Melanoma Treatment Reviewed and Strengthened Scancell's Plan for A Phase 2/3 Registration Study Following Completion of the Ongoing Scope Study

Scancell Holdings plc Appoints Florian Reinaud to the Board

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Market cap size

Scancell Holdings plc Appoints Sath Nirmalananthan to the Board

Scancell Holdings plc Directorate and Executive Changes Changes

Scancell Holdings plc to Report First Half, 2024 Results on Jan 30, 2024

Scancell Holdings plc Announces Update on SCOPE Trial

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £11.897217 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £12.672161 million.

Scancell Holdings plc has filed a Follow-on Equity Offering in the amount of £8.08 million.

Scancell Holdings plc, Annual General Meeting, Nov 29, 2023

Scancell Holdings plc to Report Q4, 2023 Results on Oct 12, 2023

Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free

Scancell Holdings plc Announces Positive Data from the First Stage in its Phase 2 Scope Trial with SCIB1 Cancer Vaccine Delivered by Needle Free Injection for Advanced Melanoma

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets SCIB1/iSCIB-1+ and Modi-1

Scancell Holdings plc Announces Appointment of Dr Mandeep Sehmi as Head of Business Development

Scancell Appoints Sath Nirmalananthan as CFO

New minor risk - Financial data availability

New minor risk - Market cap size

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Provides an Update on Its Two Ongoing Phase 1/2 Clinical Trials with Lead Cancer Vaccine Assets Scib1/Iscib-1+ and Modi-1

Scancell Holdings plc Announces Positive Response in Covidity Trial

Scancell Holdings plc Announces Executive Changes

Scancell Holdings plc to Report First Half, 2023 Results on Jan 25, 2023

Less than half of directors are independent

Scancell Holdings plc Announces First Patient Dosed in Expansion Phase of Modify

Scancell Holdings plc, Annual General Meeting, Nov 21, 2022

Scancell Holdings plc Announces Board Changes

Scancell Holdings plc Announces First Patient Dosed in Cohort 2 of the ModiFY Phase 1 Clinical Trial

Scancell Holdings plc to Produce TCB Antibodies

Scancell Holdings plc Announces an Update to the Phase 2 Scope Clinical Trial

Scancell Holdings plc Announces the Enrolment and Treatment of the First Patient in Its Multicentre Modi-1 Clinical Trial (Modify) At Imperial College London, Hammersmith Hospital

Less than half of directors are independent

Scancell Holdings plc Announces Modi-1 Phase 1/2 Trial Open for Recruitment

Scancell Holdings plc Announces Update on Covidity Clinical Trial

Scancell Holdings plc Announcedsfurther Progress of the Phase 1 Covidity Clinical Trial Being Conducted At the University of Cape Town (UCT) Lung Institute in South Africa

Scancell Holdings plc Announces the UK's Medicines and Healthcare Products Regulatory Authority Approves the Clinical Trial Application to Initiate the First-in-Human Phase I/II Clinical Study of Modi-1

CEO & Director Clifford Holloway has left the company

Scancell Holdings plc Announces COVIDITY Phase 1 Clinical Trial Planned in South Africa and UK for Novel Bivalent COVID-19 Vaccine

New 90-day high: €0.35

Scancell Holdings plc Announces an Update on its SCIB2 Clinical Development Partnership with Cancer Research UK

Scancell Holdings plc Appoints Gillies O'Bryan-Tear as Chief Medical Officer and Robert Miller as Medical Director

Scancell Holdings plc to Report Fiscal Year 2020 Results on Oct 16, 2020

Cobra Biologics and Scancell Holdings plc Announces Collaboration to Manufacture COVID-19 Vaccine

Scancell Holdings plc announced that it expects to receive £1.3 million in funding from Cherwell Capital plc, Oxford Technology Management Limited, Oxford Capital Partners LLP, Seneca Partners Limited, Octopus Investments Limited

Scancell Holdings plc has completed a Follow-on Equity Offering in the amount of £9.007417 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken